In the UK and worldwide, VTE is a leading cause of death and disability.
A scientific review by the World Thrombosis Day steering committee revealed that:
- VTE can affect anyone regardless of age, gender, race or ethnicity
- Full VTE-related costs to the NHS are difficult to extract and can go undocumented, but in the APPG for Thrombosis, annual report 2016/17, a survey of CCGs asked what their recorded costs for VTE treatment, hospital bed days, sanctions and litigation, for 2016/17.
Of the 22% of CCGs providing figures, the average annual cost for 2016/17 was £938,357 per CCG
(range spread from £63,358 South Lincolnshire to £7million in the Cambridge and Peterborough CCG area)
If this figure was to be averaged across all 211 CCGs in England this would be a cost to NHS services of £197,993,327
“Taking proactive steps to mandate VTE best practice locally could help to reduce this cost burden, however most CCGs appear to be unaware of what VTE is costing locally.”
- In Europe, there are 544,000 VTE-related deaths every year
- In the U.S. and Europe, VTE-related events kill more people than AIDS, breast cancer, prostate cancer and motor vehicle crashes combined
- In the UK, up to 55% of VTE cases occur during or after hospitalization, making it a leading preventable cause of hospital deat
- Hospital-acquired thrombosis
- Two thirds of deaths are caused by ‘hospital-acquired’ thrombosis
- Hospital-acquired blood clots cause an estimated 25,000 preventable deaths each year
- This accounts for 10% of all patients who die in hospital – and is : the number one cause of preventable hospital mortality